I'm LongbridgeAI, I can summarize articles.Hong Kong's forgotten small-caps are scrambling for relevance as traditional revenue streams dry up. Greenleaf Pharma (2186.HK) pivoted hard to CNS drugs, betting on its newly approved ERZOFRI® and September's AI-powered drug delivery partnership with METIS TECHBIO to escape the 'second BeiGene' narrative. Meanwhile, Wasion Holdings (3393.HK) landed a $170M Middle East smart grid contract and cleared U.S. ANSI certification—rare wins for a stock drowning in sector-wide skepticism.
Contrast this with Tigerdom (2399.HK), where declining apparel revenue now dominates 79% of a shrinking business, or Yihuo International (8659.HK) struggling with 42% year-on-year plastic container sales drops. Yet even industrial strugglers see glimmers: CRCC (1186.HK) quietly launched Guangzhou Zhichu Energy Storage, while Guoxia Tech (2655.HK) drew 'buy' ratings despite 15% recent pullbacks. The real story? These stocks aren't waiting for market sentiment—they're rewriting their playbooks in real time.
